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ABSTRACT

A non-human transgenic mammalian animal, as described
above, contains an exogenous double stranded DNA
sequence stably integrated into the genome of the animal,
which comprises cis-acting regulatory units operably linked
to a DNA sequence encoding human FIX protein without the
benefit of the presence of a complete milk gene sequence for
gene rescue, and a signal sequence is active in directing newly
expressed Factor IX into the milk of the animal at levels in an
unactivated form that is suitable for Subsequent processing
for therapeutic applications in treating Hemophilia B. The
transgenic mammals are preferably pigs, cows, sheep, goats
and rabbits. The applications include milk derivatives for oral
delivery and oral tolerization in the treatment of Hemophilia
B.
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PRODUCTION OF HIGH LEVELS OF
TRANSGENCFACTORIX WITHOUT GENE

RESCUE, AND ITS THERAPEUTIC USES

This application is a continuation under 37 C.F.R.S 1.53(b)
of patent application Ser. No. 10/471,492 filed on Feb. 12,

5

2004, now abandoned which is a 371 of PCT/US02/07532,
filed Mar. 11, 2002, which claims benefit of U.S. Provisional

Application No. 60/274,983 filed Mar. 12, 2001, each of
which are incorporated herein by reference in their entirety.
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FIELD OF THE INVENTION

The invention provides, among other things, a system for
producing transgenic proteins, compositions comprising
transgenic proteins, transgenic organisms for making pro
teins, for modifying transgenic proteins in vivo. Illustrative
embodiments of the invention particularly provide transgenic
animals that express an exogenous gene for vitamin K-depen
dent proteins, protease inhibitors, blood clotting proteins and
mammalian relaxins. In a highly particular illustrative
embodiment in this regard the invention provides transgenic
female pigs that express these same proteins in their milk in a
temporally controlled manner during lactation using a multi
gene inducible system. In this regard, the invention relates
particularly to female pigs having stably incorporated in their
genomes non-endogenous DNA comprising a region that
encodes these same proteins operably linked to a multi-gene
system containing at least two different promoters in separate
DNA constructs, where one of these promoters is a non
mammary gland specific promoter. Further in this regard the
invention relates to the mill containing these same proteins
and corresponding compositions derived from the milk. And
it also relates to, among other things, uses of these proteins in
wellness and therapeutic applications.
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BACKGROUND

The concept of producing important pharmaceutical and
nutriceutical proteins in transgenic animals is now firmly
established (Van Cott, K. E. and Velander, W. H., Exp. Opin.
Invest. Drugs, 7(10): 1683-1690 (1998)), with three potential
products, alpha-1 antitrypsin, antithrombin III and alpha glu
cosidase in the late stages of clinical trials. These proteins,
and nearly all other transgenic polypeptides being developed
commercially, were produced from a single DNA construct
designed to produce a single polypeptide. In general terms,
this “classical design incorporates three distinct regions of
DNA, which are all joined or operably linked in one contigu
ous Strand.
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The first region of DNA is a tissue specific promoter, in the
above mentioned examples a milk protein promoter, which
directs expression of the gene to a target organ, the mammary
gland, which is regulated by lactogenic hormones, growth
factors, cell-cell and cell-substratum interactions. The second

region of DNA is the coding region, which may consist of
complimentary DNA (cDNA, containing no introns),
genomic DNA (gDNA) or a combination of both in a format
called a mini-gene. It is important to note that cDNAs, and
perhaps also minigenes, have a silencing effect (failure to
express or poor expression levels) on adjacent transgenes
(Clark, A. J., et al., NAR, 25 (5), 1009-1014, 1997). There
fore, a method of overcoming this silencing effect using non
genomic DNA sequences is highly desirable. The coding
region contains the information needed to produce a specific
protein, including any processing and secretory signals. The
third region, the 3' region, contains further regulatory
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2
sequences and may influence the quantity of polypeptide that
is produced from that construct. Non-genomic DNA
sequences are inherently smaller than g|DNA sequences and
are therefore, much easier to manipulate in classical trans
gene formats.
Although this classical design has been Successful in pro
ducing commercially viable quantities of certain proteins,
there are two areas in which this system is not optimal. First,
it is generally accepted that using cDNAS or minigenes in a
classically designed construct, is less efficient for protein
production than using a corresponding gCNA coding region.
Indeed, this is such a problem that methods have been devel
oped to address this issue (Clark, A. J. et al. Biotechnology
10, 1450-1454, 1992). Whilst these methods can improve the
efficiency and level of expression of cDNAs and minigenes to
Some extent, they do not improve expression to the same level
as is typically obtained using gCNA. A higher level would be
ideal for commercial protein production.
The second area in which the classical single gene DNA
construct design is Suboptimal is in the production of highly
biologically active proteins in transgenic animals. Proteins
with an extremely high biological activity can be detrimental
to the transgenic animal, even if circulatory levels (or other
systemic levels) are low (Castro, F. O., et al., Selection of
Genes for Expression in Milk: The Case of the Human EPO
Gene, in Mammary Gland Transgenesis. Therapeutic Protein
Production. Castro and Janne (eds.) Springer-Verlag Berlin
N.Y., 91-106, 1998). This can be due in large part to either
ectopic expression (expression of the transgene in organs
other than the targeted one) or leakage of the protein product
into the blood from the target organ. If the protein product is
highly biologically active, expression ideally must be strictly
controlled so that the animal is exposed to the product for a
short time only, thus reducing the chance of any lasting det
rimental effects. This requires an expression system that can
be turned on and off very rapidly and precisely.
Regulation of Promoters
The expression of many genes is controlled at the level of
transcription, when the DNA sequences are transcribed into
RNA, prior to being translated into protein (Latchman, D. S.,
Eukaryotic Transcription Factors, Academic Press, 1998).
The DNA sequence element that controls transcription is the
promoter. This generally contains a small core region, which
is capable of directing constitutive or basal levels of transcrip
tion, and upstream response elements that control spatial and
temporal regulation of transcription. These DNA sequences
include two types of elements, those which are involved in the
basic process of transcription and are found in many genes
exhibiting distinct patterns of regulation, and those found
only in genes transcribed in a particular tissue or in response
to a specific signal. The latter elements likely produce this
specific expression pattern. They are binding sites for a wide
range of different cellular proteins (transcription factors)
whose levels fluctuate in response to stimuli from external or
internal Sources, Gene expression in a given tissue may be
stimulated or inhibited depending on the type and amount of
transcription factors that are present in that tissue at any time.
Many transcription factors or other proteins that enable tran
Scription factor pathways are largely uncharacterized from
the perspective of an exact biochemical analysis, which
details their conformationally-dependent interactions with
DNA. Overall, the regulation of expression at the DNA level,
is a function of which regulatory elements (binding sites) are
present in the promoter and how the cell or tissue responds to
its environment by changing the relative levels of the different
DNA binding transcription factors in the cell.
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Another mechanism involved in the precise control of gene
expression is transcriptional repression (Maldonado, E., et al.
Cell, 99(5), 455-458, 1999). Transcriptional repressor pro
teins associate with their target genes either directly through
a DNA-binding domain or indirectly by interacting with other
DNA-bound proteins. The repressor protein can inhibit tran
Scription by masking a transcriptional activation domain,
blocking the interaction of an activator with other transcrip
tion components or by displacing an activator from the DNA.
Milk protein genes are characterized by a strict tissue spe
cific expression and regulation during the process of func
tional differentiation. They are coordinately expressed in
response to various developmental signals, such as changing
levels of lactogenic hormones (prolactin, insulin, glucocorti
coids, progesterone), local levels of certain growth factors
(EGF), cell-cell interactions and interactions with extra-cel
lular matrix (ECM) components (Rijnkels, M. and Pieper, F.
R., Casein Gene-Based Mammary Gland-Specific Transgene
Expression, in Mammary Gland Transgenesis. Therapeutic
Protein Production. Castro and Janne (eds.) Springer-Verlag,
Berlin, N.Y., 41-64, 1998).
Lactogenic hormones activate latent transcription factors
in the cytoplasm of mammary epithelial cells. The steroid
hormones progesterone, estrogen, and glucocorticoid regu
late the transcription of target genes by binding to specific
intracellular receptors. Some models purport that binding of
the hormone with its receptor changes the receptors confor
mation from a physiologically inactive form to a form which
is active and capable of dimerization. The active receptors are
then capable of binding specific DNA sites in the regulatory
region of the target gene promoters, stimulating gene tran
scription and thus, protein synthesis. Steroid receptors belong
to a Superfamily of ligand-inducible transcription factors and
it has been well documented that these are modular proteins
organized into structurally and functionally defined domains.
It has also been shown that these domains can be rearranged
as independent cassettes within their own molecules or as
hybrid molecules with domains from other regulatory pep
tides. Interestingly, the transactivation domains of the gluco
corticoid receptor can be duplicated in tandem and show
positional independence in a “super receptor with 3-4 times
the activity of the wild type protein. (Hollenberg, S. M. and

10

lates nuclear translocation and mediates the interaction
15

25

30

35

40

45

32-33, 110-122, 1999: Braselmann, S., etal, PNAS,90, 1657

1666, 1993). The structure and function of the steroid recep
tor superfamily is well conserved. Generally there are three
main domains and several Sub-domains or regions. The NH2
terminal domain is the least conserved in size and sequence
and contains one of the two, transactivation sequences of the
receptor. The central DNA binding domain of about 70 amino
acids is highly conserved, as is the COOH-terminal ligand
binding domain. This latter domain also contains Sub-do
mains responsible for dimerization, heat shock protein (lisp)
90 binding, nuclear localization and transactivation.
Prolactin plays the essential role in milk protein gene
expression and exerts its effect through binding to the extra
cellular domain of the prolactin receptor and through receptor
dimerization. This activates a protein tyrosine kinase (JAK2)
which is non-covalently associated with the cytoplasmic
domain of the prolactin receptor (Gouilleux, F., et al., EMBO
J., 13(18), 4361-4369, 1994: Imada, K. and Leonard, W.J.,
Mol. Immunol. 37 (1-2), 1-11, 2000). The activated JAK2
phosphorylates the signal transducer and transcription acti
vator, Stat 5, causing it to dimerize and Subsequently, trans
locate to the nucleus. Once in the nucleus, Stats specifically

between Stat dimers (Callus, B. A. and Mathey-Prevot, B., J.
Biol. Chem., 275(22), 16954-16962, 2000). There is a central
DNA binding domain and a carboxy terminal region, which
contains the phosphorylation site and a transactivation
domain.

Evans, R. M., Cell, 55, 899-906, 1988: Fuller, P.J., FASEB.J.,
5,3092-3099, 1991; U.S. Pat. No. 5,364,791; U.S. Pat. No.

5,935,934: Whitfield, G. K., et al., J. Cell. Biochem., suppl.

4
binds to sequence elements in the promoter regions of milk
protein genes (Liu, X., et al., PNAS, 92, 8831-8835, 1995:
Cella, N., et al. Mol. Cell. Biol., 18(4), 1783-1792, 1998:
Mayr, S., et al., Eur. J. Biochem., 258(2), 784-793, 1998). In
an analysis of 28 milk protein gene promoters (Malewski, T.,
BioSystems, 45,29-44, 1998) there were 4 transcription fac
tor binding sites that were present in every promoter, C/EBP.
CTF/NF1 MAF and MGF (Stat5). Although steroid hormone
receptors and Stat factors comprise two distinct families of
inducible transcription factors their basic structure is similar.
Stat proteins are modular with an amino terminus that regu
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Egg white genes seem to be regulated in a similarly com
plex manner. It is known that the progesterone-dependent
activation of the egg white genes in the chicken oviduct is
mediated through the progesterone receptor (Dobson, A. D.
W., et al., J. Biol. Chem., 264(7), 4207-4211, 1989). In addi
tion, the chicken ovalbumin upstream promoter-transcription
factor (COUP-TF) is a high affinity and specific DNA binding
protein, which interacts as a dimer with the distal promoter
sequence of the ovalbumin gene and promotes initiation of
transcription of this gene by RNA polymerase (O'Malley, B.
W. and Tsai, M-J., Biol. Reprod., 46,163-167, 1992). COUP
TFs are orphan members (no binding ligand has as yet been
determined for these receptors) of the nuclear receptor super
family, and have been shown to play a key role in the regula
tion of organogenesis, neurogenesis, metabolic enzyme pro
duction and cellular differentiation during embryogenic
development, via transcriptional repression and activation
(Sugiyama, T., et al., J. Biol. Chem..., 275(5), 3446-3454,
2000).
A protein expression method based on the inducible Tet
repressor system has been developed (Furth, P. A., et al.
PNAS, 91, 9302-9306, 1994), but the levels of basal expres
sion without induction are too high to be useful in transgenic
animals (Soulier S. et al., Eur. J. Biochem. 260, 533-539,
1999). Another inducible system based on the use of the
ecdysone receptor has been reported (No, D., et al., PNAS, 93,
3346-3351, 1996: PCT 97/38117, PCT 99/58.155) and has
recently given encouraging results in transgenic mice (Al
banese, C. etal, FASEB.J., 14,877-884, 2000). However, this
system required the delivery of an exogenous ligand to the
mice for the full lactation period. Such a ligand would be
costly and difficult to procure for regular administration in a
production environment.
A new multi-gene system for protein production in trans
genic animals would improve commercial levels of produc
tion from cDNA constructs by amplifying specifically tai
lored transcription factors which need not naturally occur in
the tissue targeted for expression, but would be transgenically
expressed specifically in that tissue. Unlike classical gene
expression formats for recombinant proteins, the tissue spe
cific promoter would not be linked to the protein to be
expressed, but would be used to drive expression of transcrip
tion factors which do not have a signal sequence and so are not
secreted. In addition, the added control that a doubly induc
ible multi-gene system would provide, which is inexpensive
and easily applied, could enable the production of highly
biologically active proteins in transgenic animals in a pulsa
tile fashion so as to avoid longterm detrimental effects.
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Proteins for Transgenic Production
A multi-gene system, as described below, can be used to
direct expression of any protein, particularly any secreted
protein, which can be expressed in a transgenic organism in
useful quantities, either for research or commercial develop
ment. Particular proteins of interest with respect to produc
tion by multi-gene expression systems include relaxin and
other hormones with cross-species activity Such as growth
factors, erythropoitin (EPO) and other blood cell growth
stimulating factors. For these proteins, the expression may be
problematic in terms of harming the host animal as is known
to happen when EPO is expressed for an extended period of
time. It is noted that tissue specific expression of transgenesis
not an absolute phenomenon and promiscuous expression or
systemic transport of the expressed recombinant protein
within the animal almost always occurs with any expression
system in any animal, albeit at very low levels. However, even
at low levels of expression of EPO, when the EPO is
expressed over an extended period of time, the hematocrit of
the host animal can rise to a fatal level. Thus a temporal
control which can enable pulse expression using an external
inducer molecule could overcome the problems of continu
ous and extended expression (ie., as could occur if expression
occurs over an entire lactation period). Pulse or truncated
expression would be useful in preventing an adverse, sys
temic physiologic effect by recombinant molecules like EPO,
which can cause these effects at very low levels.
Relaxin is widely known as a hormone of pregnancy and
parturition and typically circulates at less than 50 pg/ml in the
blood of women. However, it is now emerging that the peptide
has a far wider biological function than was at first thought.
There are receptor sites for relaxin in striated muscle, smooth
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muscle, cardiac muscle, connective tissue, the autonomic and

the central nervous systems. Human relaxin has been dem
onstrated to inhibit excessive connective tissue build-up and

35

is in Phase II trials for the treatment of Scleroderma. Porcine

relaxin was available commercially in the 1950-60s and was
used extensively for Such conditions as cervical ripening,
scleroderma, premature labour, PMS, decubital ulcers and
glaucoma. Relaxin is known to adversely affect the lactation
of different mammalian species but does not seem to affect
the pig in a similar manner. Therefore, the pig is perfectly
suited for production of relaxin in milk.
Other examples of proteins which it would be desirable to
produce in transgenic organisms, are proteins that are pro
tease inhibitors. Some examples of protease inhibitors are
Alpha 1-antitrypsin, Alpha 2 Macroglobulin, and serum leu
kocyte protease inhibitor. These proteins are serine protease

TABLE 1

VKD proteins.

40

Protein C

Factor X(FX)

Protein S
Protein Z.
Factor IX

Prothrombin
Factor VII

Bone Gla protein (Osteocalcin)

45

inhibitors that show antiviral, non-steroidal anti-inflamma

tory and wound healing properties. These proteins are useful
in Veterinary, cosmetic and nutriceutical applications.
Alpha 1-antitrypsin (AAT) is a naturally occurring glyco
protein produced by the liver. Improperly glycosylated
recombinant AAT Such as made by yeast, does not have a
sufficient circulation half-life to be used as a parenterally
administered therapeutic. Congenital deficiency results in the
condition emphysema and in 1985 Bayer Pharmaceuticals
began marketing a plasma derived AAT product, Prolastin.
Unfortunately, due to shortages of Asafe(a) plasma and fre
quent recalls, supplies of Prolastin are often very limited.
AAT has also been used to treat psoriasis, atopic dermatitis,
ear inflammation, cystic fibrosis and emphysema, and to
assist in wound healing. It has been estimated that over 10
million people in the US alone may benefit from AAT thera
pies.
Alpha 2 macroglobulin (A2M) is a very large, complex
glycoprotein with a published cDNA sequence containing

6
1451 amino acids. The mature protein is a tetrameric mol
ecule composed of four 180 kDa subunits and thus has a
molecular weight which is over 720 kDa. Its complexity
makes it most Suited for production in mammalian systems
but few mammalian systems will likely make A2M at com
mercially viable levels. A2M is indicated for treatment of
asthma, bronchial inflammation and eczema and acts as a
protease inhibitor to both endogenous and exogenous pro
teases that cause inflammation. A2M is necessarily more
potent than alpha 1-antitrypsin due to its irreversible binding
of target proteases. A2M is also useful in inhibiting proteases
frequently found in (thermal) burn wounds from yeast and
other infections. The high specific activity of these types of
proteases allows for Smaller doses during treatment. Thus,
A2M-s complexity and specific activity make it ideally
Suited for production in transgenic pig mammary glands.
Vitamin K-Dependent Proteins
Vitamin K-dependent (VKD) proteins such as those pro
teins associated with haemostasis have complex functions
which are largely directed by their primary amino acid struc
ture. In particular, the post-translational modification of
glutamic acids in the amino terminal portion of these mol
ecules is essential for proper biological activity. This includes
biological activity of both pro-coagulation and anti-coagula
tion. This particular domain found in VKD-proteins is called
the 'gla domain’. For example, the Gla domain is an essential
recognition sequence in tissue factor (TF) mediated pro-co
agulation pathways. The anti-coagulation of this pathway
depends upon the lipoprotein-associated coagulation inhibi
tor, termed LACI, which is a non-VKD protein. LACI forms
a complex with the Gla domain of factor Xa, factor VIIa, and
TF. Specifically, the Gla domain of factor Xa (FXa) is needed
for this procoagulation inhibitory activity. It has been shown
that recombinant chimeric molecules having LACI inhibitor
(Kunitz type) regions and the Gla domain of FXa can be
inhibitory of the TF pathway.
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Gamma-carboxylation is required for calcium-dependent
membrane binding. All of the proteins listed in Table 1 have
multiple Gla-residues in a concentrated domain. The Gla
domains of these proteins mediate interaction and the forma
tion of multi-protein coagulation protein complexes. Mam
malian coagulation (here collectively meaning both pro
coagulation and anti-coagulation pathways and mechanisms)
physiology requires that nearly complete-carboxylation of
VKD-proteins occurs within the respective Gla domain for
each of these proteins to be maximally functional. Notably, in
the context of recombinant synthesis of any protein contain
ing Gla-domains, the extent of gamma-carboxylation of
VKD-proteins varies from one mammalian cell source to
another, including differences between species and tissue
within a species.
VKD-proteins of interest with respect to production by
single or multi gene expression systems include those in
Table 1, particularly blood clotting factor IX, Protein C and
chimeric hybrid vitamin K-dependent proteins. Factor IX is
an essential blood clotting protein. Haemophilia B is a genetic
disorder in which the production of active Factor IX is defec
tive. It is an inherited disorder that primarily affects males, at
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the rate of approximately 1 in 30,000. The consequent inabil
ity to produce sufficient active Factor IX can lead to profuse
bleeding, both internally and externally, either spontaneously
or from relatively minor injuries.
In spite of techniques available to amplify recombinant
synthesis of VKD proteins such as Protein C and Factor IX,
biologically functional recombinant versions of these pro
teins are difficult to produce and are made typically at levels
less than about 0.1 grams per liter per 24hours in recombinant
cell culture media (Grinnell, B. W., et al., in Protein C and
Related Anticoagulants. Bruley, D. F. and Drohan, W. N.
(eds.), Houston, Tex.; Gulf Publishing Company, 29-63,
1990), or less than 0.22 gm per liter per hour in the milk of
transgenic livestock (Van Cott, K. E., et al., Genetic Analysis:
Biomolecular Eng., 15, 155-160, 1999). The expression of
high levels of FIX using a cDNA construct is difficult. How
ever, the gldNA of FIX, at 33 kbp, is rather large and difficult
to manipulate, particularly when compared to the FIX cDNA,
which is only 1.4 kbp.
Most VKD-blood plasma proteins are also glycosylated.
The extent and types of glycosylation observed is heteroge
neous and varies considerably in all species and cell types
within a species. Examples of the heterogeneity, structure
function relationships of glycosylation are cited by Degen,
Seminars in Thrombosis and Hemostasis, 18(2), 230-242,
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1992; Prothrombin and Other Vitamin K Proteins, Vols I and

II, Seegers and Walz, Eds. CRC Press, Boca Raton, Fla.,
1986.

Glycosylation is a complex post translational modification
that occurs on many therapeutic proteins. The process of 30
glycosylation attaches polymeric Sugar compounds to the
backbone of a protein. These sugar-based structures impart
not only an immunologically specific signature upon the pro
tein, but also can change the specific level of activity that the
protein has with relation to how long it can reside in the 35
bloodstream of a patient, or how active the protein is in its
basic function. All three of these facets can make or break the

protein in its role as a therapeutic or wellness product. For
example, genetically engineered yeast can impart glycosyla
tion that results in an immunologically adverse signature,
which can stimulate the body to make antibodies and essen
tially reject the protein. In fact, that is part of the reason why
yeast vaccines are effective; they easily induce an immune
response. The mammary gland of ruminants produces a Sub
stantial fraction of glycosylation on milk proteins which
resemble the primitive Sugars found in yeast. Thus, applica
tions that result in the long term, repeated exposure of pro
teins containing yeast or yeast-like signatures, to human tis
sue are intensely scrutinized with respect to the potential of
adverse immune reactions. This structure is also apt to cause
dysfunction with respect to the proteins natural activity and
may also contribute to a shortened residence time in blood. In
contrast, the mammary gland of pigs gives a glycosylation
signature which more closely resembles that found in normal
human blood proteins, helping to assure biochemical function and a long circulatory half-life.
The complex post-translational modifications of therapeu
tic proteins, such as those discussed above that are necessary
for physiological activities, pose a difficult obstacle to the
production of active vitamin K dependent proteins in cells
using cloned genes. Moreover, attempts to culture genetically
altered cells to produce VKD polypeptides have produced
uneconomically low yields and, generally, preparations of
low specific activity. Apparently, the post-translational modi
fication systems in the host cells could not keep pace with
production of exogenously encoded protein, reducing spe
cific activity. Therefore, cell culture production methods have
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not provided the hoped for advantages for producing highly
complex proteins reliably and economically.
An attractive alternative is to produce these complex pro
teins in transgenic organisms. However, it is likely that only
mammals and perhaps birds will be able to carry out all the
post-translational modifications necessary for their physi
ological function. It has not been possible, as yet, to produce
commercially viable levels of certain complex polypeptides
from a controlled source in a highly active form with a good
yield, and there exists a need for better methods to produce
Such proteins.
An interesting new class of proteins, which is likely to be
difficult to produce in commercial quantities in cell culture
are the genetically engineered fusion, chimeric and hybrid
molecules which are now being developed. These proteins are
designed and produced by combining various domains or
regions from different natural proteins, either wild type or
mutated, which can confer the properties of each domain or
region to the final hybrid molecule. An example of this is
XLACI (Girard, T. J., et al., Science 248, 1421-1424,
1990) which is a hybrid protein made up of domains from
factor X and lipoprotein-associated coagulation inhibitor
(LACI). LACI appears to inhibit tissue factor (TF)-induced
blood coagulation by forming a quaternary inhibitory com
plex containing FXa. LACI, FVIIa and TF. XLACI
directly inhibits the activity of the factor VIIa-TF (tissue
factor) catalytic complex, but is not dependent on FXa.
Gamma-carboxylation of the FX portion of the hybrid protein
is required for inhibitory activity. In order for efficient car
boxylation to occur at high levels, it is likely that the pro
peptide of the recombinant VKD-protein must be properly
matched to the endogenous carboxylase system (Stanley, T.
B. etal, J. Biol. Chem., 274(24), 16940-16944, 1999). This is
probably true for all VKD-polypeptides including chimeric
ones such as XLACI. It appears that the endogenous
carboxylase systems of any given species or tissue within that
species, most of which are not identified or characterized, will
differ in their compatibility to any given pro-peptide
sequence. Also it is frequently desirable to have the pro
peptide cleaved from the nascent VKD protein, such as a
XLACI polypeptide, once gamma-carboxylation has
been completed on the polypeptide’s gla domain. It is there
fore, also important to find a propeptide sequence that will be
efficiently cleaved within the specific species and tissue in
which it is being recombinantly produced. These factors ren
der it problematic to find an expression system which can
produce desirable amounts of biologically active VKD-pro
teins such as XLACI chimeric proteins. In spite of being
known as a potent coagulation inhibitor since the early 1990s,
XLACI chimeric molecules have not been made in large
amounts in a commercially viable manner (ie., greater than
0.1 gm per liter per 24 hours) in recombinant mammaliancell
culture. One way to improve expression of this protein in a
transgenic system, particularly in transgenic pigs, may be to
substitute the FIX propeptide sequence for the FX propeptide
sequence, such a protein would be termed 9XKI.
New therapeutic molecules are being designed to have
increased activity, decreased inactivation, increased half-life
or specific activity and reduced immunogenicity and/or
immunoreactivity to existing circulating antibodies in
patients’ bloodstreams. This has been demonstrated in geneti
cally engineered Factor VIII proteins (U.S. Pat. No. 5,364,
771, U.S. Pat. No. 5,583.209, U.S. Pat. No. 5,888,974, U.S.
Pat. No. 5,004,803, U.S. Pat. No. 5,422,260, U.S. Pat. No.

65 5,451,521, U.S. Pat. No. 5,563,045). Mutations include dele
tion of the B domain (Lind, P. et al., Eur. J. Biochem. 232,
19-27, 1995), domain substitution or deletion, covalent link
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age of domains, site-specific replacement of amino acids and
mutation of certain cleavage sites. In particular, a genetically
engineered inactivation-resistant factor VIII (IR8) has been
developed to help in the treatment of hemophilia A (Pipe, S.
W. and Kaufman, R. J., PNAS 94, 11851-11856, 1997). The
introduction of specific sequences from porcine factor VIII

5

can also be useful in the formation of a recombinant FVIII

which is used to treat hemophiliacs with improved properties
as stated above. These molecules can also be designed for
improved expression. It is widely known that FVIII has
restrictions in intracellular trafficking which lead to low lev

10
Other objects, features and advantages of the present
invention will become apparent from the following detailed
description. It should be understood, however, that the
detailed description and the specific examples, while indicat
ing preferred embodiments of the invention, are given by way
of illustration only, since various changes and modifications
within the spirit and scope of the invention will become
apparent to those skilled in the art from this detailed descrip
tion.
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BRIEF DESCRIPTION OF THE DRAWINGS

els of secretion. Modification of the domains associated with

intracellular interactions with immunoglobulin binding pro
tein (Bip) or calnexin would be examples of modifications
used to improve secretory processing efficiency (Kaufman,

15

R. J. Abstract S1-8, 10" Int. Biotech. Symp., Sydney, Aus
tralia, 25-30 August, 1996). Factor VIII g|DNA is another

example of an extremely large and unwieldy DNA sequence
(-110kbp), whereas the cDNA is only 7 kbp, making it much
more manageable.
Whey acidic protein (referred to as “WAP) is a major
whey protein in the milk of mice, rats, rabbits and camels. The
regulatory elements of the mouse WAP gene are entered in
GenBank (U38816) and cloned WAP gene DNAs are avail
able from the ATCC. The WAP promoter has been used suc
cessfully to direct the expression of many different heterolo
gous proteins in transgenic animals for a number a years
(EP0264166, Bayna, E. M. and Rosen, J. M., NAR, 18(10),
2977-2985, 1990). Lubon etal (U.S. Pat. No. 5,831,141) have
used a long mouse WAP promoter (up to 4.2 kbp) to produce
Protein C in transgenic animals. However, the longest rat
WAP promoter that has been used is 949 bp (Dale, T.C., et al.,
Mol. Cell. Biol., 12(3), 905-914, 1992).
SUMMARY

The present invention is directed to producing transgenic
proteins, compositions comprising transgenic proteins, trans
genic organisms for making proteins, for modifying trans
genic proteins in Vivo, and to addressing the previously-dis
cussed issues, e.g., as characterized in connection with the
above-cited references each of which is incorporated by ref
erence generally and more specifically as such teachings
relate to methodology for related transgenic protein produc
tion and applications of Such proteins.
In various embodiments of the present invention there is a
composition for treating hemophilia B comprising a milk
derivative containing recombinant human factor IX derived
from a bodily fluid produced in a transgenic organism as

invention.
25

FIG. 4 is the production of puCWAP6, according to yet
another example embodiment of the present invention.
While the invention is amenable to various modifications

and alternative forms, specifics thereof have been shown by
way of example in the drawings and will be described in
detail. It should be understood, however, that the intention is
30

not necessarily to limit the invention to the particular embodi
ments described. On the contrary, the intention is to cover all
modifications, equivalents, and alternatives falling within the
spirit and scope of the invention as defined by the appended
claims.

35

DETAILED DESCRIPTION

40

45

50

described below.

In other more specific embodiments, the present invention
is directed to a non-human transgenic mammal containing an
exogenous DNA molecule stably integrated in its genome.
The exogenous DNA molecule comprises: (a) a mammary
gland-specific gene including a promoter; (b) a Factor IX
encoding DNA sequence that encodes the endogenous secre
tion-signal sequence, a Factor IX pro-sequence and a Factor
IX sequence; (c) 3' regulatory sequences from a mammary
gland-specific gene, which sequences are operatively linked
to said Factor IX-encoding DNA sequence; (d) the stably
integrated exogenous DNA does not include a WAP milk
protein gene for providing gene rescue to achieve expression
of the Factor 1xDNA; and (e) said Factor IX is secreted into
the milk at least 220 micrograms Factor IX per milliliter of
milk and is not activated by the milk-environment and there
fore useable for Factor IX therapeutic applications.

The invention may be more completely understood in con
sideration of the detailed description of various embodiments
of the invention in connection with the accompanying draw
ings, in which:
FIG. 1 is assembly of the plasmid pWAPFIX, according to
an example embodiment of the present invention;
FIG. 2 is assembly of the plasmid pUCWAPFIX, according
to another example embodiment of the present invention; and
FIG. 3 is production of the modified plasmid puCNot1.
according to yet another example embodiment of the present

55

As previously mentioned, the present invention is directed
to products and approaches for regulating the expression of a
protein in a transgenic organism, methods for obtaining
polypeptides from transgenic organisms, compositions com
prising transgenically produced polypeptides, and uses
thereof. For example, one embodiment of the present inven
tion is directed to a non-human transgenic mammal contain
ing an exogenous DNA molecule that is stably integrated in
its genome. The exogenous DNA molecule includes a mam
mary gland-specific gene, a Factor IX-encoding DNA
sequence that performs encoding for applicable sequences,
and 3' regulatory sequences from a mammary gland-specific
gene. Surprisingly, in connection with the present invention,
it has been discovered that, with the 5' and 3' regulatory
sequences that are operatively linked to the Factor IX-encod
ing DNA sequence with the stably integrated exogenous
DNA not including a WAP milk protein gene for providing
gene rescue to achieve expression of the Factor IX DNA, the
Factor IX can be made and secreted into the milk, so that the

60
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Factor IX containing milk can be made suitable for Factor IX
therapeutic applications.
Methods for Making Transgenic Organisms
Transgenic organisms may be produced in accordance with
the invention as described herein using a wide variety of
well-known techniques, such as those described in Perry, M.
M. and Sang, H.M., Transgenic Res. 2, 125-133; Ho Hong, Y.
et al., Transgenic Res. 7(4), 247-252, 1998; Genetic Engi
neering Of Animals, Ed. A. Puhler, VCH Publishers, New
York (1993) and in more detail in Volume 18 in Methods in
Molecular Biology: Transgenesis Techniques, Eds. D. Mur
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phy and D. A. Carter, Humana Press, Totowa, N.J. (1993); all
of which are incorporated herein by reference in their entire
ties, particularly as to the foregoing in parts pertinent to
methods for making transgenic organisms that express
polypeptides. See also for instance Lubon et al., Transfusion
Medicine ReviewsX (2): 131-141 (1996) and Pursel, V.G., et

5

al., 480 in the proceedings of 11" International Congress on

Animal Reproduction and Artificial Insemination, Dublin,
Ireland, 1988, which are incorporated herein by reference in
their entirety, particularly as to the foregoing in parts perti
nent to methods for making transgenic organisms.
In particular, transgenic mammals, such as mice and pigs,
that express polypeptides in accordance with certain pre
ferred embodiments of the invention, can be produced using
methods described in among others Manipulating The Mouse
Embryo, Hogan et al., Cold Spring Harbor Press (1986);
Krimpenfort et al., Bio/Technology 9: 844 et seq. (1991);
Palmiter et al., Cell 42: 343 et seq. (1985); Genetic Manipu
lation of the Early Mammalian Embryo, Kraemer et al., Cold
Spring Harbor Press, Cold Spring Harbor, N.Y. (1985): Ham
mer et al., Nature 315: 680 et seq. (1985); U.S. Pat. No.
4,873,191 of Wagner et al. for Genetic Transformation of
Zygotes, and U.S. Pat. No. 5,175.384 of Krimpenfort et al. for
Transgenic Mice Depleted in Mature T-Cells and Methods for
Making Transgenic Mice, each of which is incorporated
herein by reference in its entirety, particularly as to the fore
going in parts pertinent to producing transgenic mammals by
introducing DNA or DNA:RNA constructs for polypeptide
expression into cells or embryos.
For example, transgenic organisms of the present invention
can be produced by introducing into eggs, or developing
embryos, one or more genetic constructs that engender
expression of polypeptides as described herein. In certain
preferred embodiments of the invention, DNAs that comprise
cis-acting transcription controls for expressing a polypeptide
operably linked to a region encoding the polypeptide are
highly preferred. In other preferred embodiments a multi
gene system directing expression of a polypeptide and con
taining the DNA sequences coding for Such a polypeptide, are
highly preferred. Also highly preferred in this regard are
single and or multi-gene constructs as described herein, that
engender expression of genetically engineered genes for
polypeptides. Constructs that comprise operable signal
sequences that effectuate transport of the polypeptide product
into a targeted compartment of an organism, Such as a tissue
or fluid, are further preferred in certain embodiments in this
regard. Also especially preferred in this regard are constructs
that are stably incorporated in the genome of germ line cells
of the mature organism and inherited in normal, Mendelian
fashion upon reproduction. One or more DNA or RNA:DNA
hybrids or the like may be used alone or together to make
transgenic organisms useful in the invention as described

tion.
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those disclosed below.

Constructs can be introduced using these and other meth
ods into differentiated cells, such as fibroblast cells, which are

In a preferred method, developing embryos can be infected
with retroviral vectors and transgenic animals can be formed
from the infected embryos. In a particularly preferred method
DNAs in accordance with the invention are injected into
embryos, at the single-cell or several cell stage. In some
particularly preferred embodiments in this regard, DNA is
injected into the pronucleus of a one-cell embryo. In other
preferred embodiments in this regard. DNA is injected into
the cytoplasm of a one-cell embryo. In yet another particu
larly preferred embodiment in this regard, DNA is injected
into an early stage embryo containing several cells.
The following examples are provided merely to illustrate
the invention, and are not to be interpreted as limiting the
scope of the invention which is described in the specification
and appended claims.
It is important to note that recombinant human Factor IX
(rhFIX) and “FIX' made by a transgenic animal are here
terms for the same species. The Short WAP-FIX-cDNA is a
genetic construct described below and is a term for the genetic
construction using the 2.5 kbp fragment of the mouse WAP
promoter operably linked to the cDNA of FIX. The Long
WAP-FIX-cDNA is a genetic construct described below and
is a term for the genetic construction using the 4.1 kbp frag
ment of the mouse WAP promoter operably linked to the
cDNA of FIX.
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Example 1
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further below.

Standard, as well as unusual and new techniques for mak
ing transgenic organisms generally can be used to make trans
genic organisms in accordance with the invention. Useful
techniques in this regard include, but are not limited to, those
that introduce genetic constructs by injection, infection,
transfection—such as calcium phosphate transfection, using
cation reagents, using sperm or sperm heads or the like—
lipofection, liposome fusion, electroporation, and ballistic
bombardment. Useful techniques include both those that
involve homologous recombination, which can be employed
to achieve targeted integration, and those that do not, such as

12
capable of being reprogrammed and then cloned, pluripotent
cells, totipotent cells, germ line cells, eggs, embryos at the
one cell stage, and embryos at several cell stages, among
others, to make transgenic organisms of the invention. In
these regards, among others, they may be introduced by Such
methods into pronuclear, nuclear, cytoplasmic or other cell
compartments or into extracellular compartments of multi
cellular systems to make transgenic organisms of the inven
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Construction and preparation of the 2.5 kbp WAP driven
FIX-cDNA (short WAP-FIX-cDNA) construct to be used
without gene rescue from a milk protein gene for microinjec
tion into transgenic animals:
Generally, for achieving single gene expression systems
for the transgenic animals described above, several parts of
the entire murine WAP gene, which included the 2.5 kbp of
5'-untranslated promoter sequence and 3' untranslated
regions (3'-UTR) were used and cloned by standard methods.
See Campbell et al., Nucleic Acids Res. 12:8685 (1984). A
cDNA fragment encoding human Factor IX was obtained
such that the 3' untranslated region of the FIX cDNA was
deleted. Using standard methods, an expression vector was
constructed so that it contained a mouse WAP promoter,
isolated as a 2.5 kbp EcoRI-KpnI fragment immediately 5' to
the WAP signal sequence (the “short WAP promoter”), the
human Factor IX cDNA (FIX-cDNA) sequence lacking a 3
untranslated region, and a 1.6 kbp fragment of the 3' untrans
lated region of the WAP gene. Expression vectors were ampli
fied by bacterial transformation and purified from bacterial
cultures using standard methods. Routine recombinant DNA
techniques can be found, for example, in Sambrook et al.,
MOLECULAR CLONING, A LABORATORY MANUAL,

Vol. 1-3 (Cold Spring Harbor Press 1989.
More specifically, a chimeric 2.5 kbp WAP 5'-promoter
Factor IX-3' WAP UTR construct was prepared, as follows:
Step 1: Production of pWAP4 “cassette vector”
Regulatory 5' and 3’ flanking sequences of the mouse WAP
gene were used as a source of the mammary specific expres
sion system (Vector containing WAP gene a gift from Lothar
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Hennighausen, NIH). Specifically, a cassette vector contain
ing a mouse WAP promoter, defined as a 2.5 kbp EcoRI-KpnI
fragment (known as the “short WAP promoter) immediately
5' to the WAP signal sequence and a 1.5 kbp fragment of the
3'-untranslated region of the WAP gene was prepared. These
regulatory sequences do not include coding and intragenic
untranslated sequences (introns) of the WAP gene. The vector
designated pWAP4 was derived from pWAPPC3 (C. Russell,
dissertation “Improvement of Expression of Recombinant
Human Protein C in the Milk of Transgenic Mammal Using a
Novel Transgenic Construct. Virginia Polytechnic Institute,
Blacksburg, Va. (December 1993)) and was developed as
follows: Using WAPPC3 as a template, PCR primers
WAP3'S2 (which contains a 5'KpnI site and is homologous to
endogenous WAP right after the stop signal) and WAP3'A1,
were used to produce a segment with KpnI and BamHI sites
on either end. This segment was digested with KpnI/BamHI
and ligated with 68 bp containing the 5' end of the WAP 3'
UTRKpnI\BamHIdigested pWAPPC3 to remove the protein
C coding region and insert an unique Kipn I cloning site. The
ligation mixture was used to transform E. coli DH5C. cells by
electroporation with resultant colonies grown on LB ampi
cillin plates. Picked colonies were grown up in TBampicillin
broth, plasmids isolated and cut with KpnI, BamHI or both
and Subjected to gel electrophoresis. Sequencing was per
formed using WAP3'A1 primer and judged as being correct.
Step 2: The FIX cDNA (containing Kpn I sites located
immediately before the start sequence and after the stop
sequence) was generated as a PCR fragment. Fragment pro
duction protocol is as follows: 100 ul total volume containing
200 uM dNTPs, 0.5uM of each primer (humFIX5'KpnI and
humFIX3'KpnI, 2.5 units Pfu polymerase and 30 ng of plas
mid template (pMCDSFIX obtained from Prof. Darryl
Stafford, Department of Biology, University of North Caro
lina, Chapel Hill, N.C., USA), reaction mixture was subjected
to 30 cycles of denaturation at 95°C. for 20 sec, annealing at
50° C. for 1 min and elongation at 75° C. for 5 min 45 sec.
After cycling, the reaction mixture was subjected to blunting
with T4 DNA polymerase for 10 min, EDTA concentration
brought up to 25 mM, heated to 65° C. for 15 min, and
extracted with Phenol:Chloroform (1:1), precipitated with
equal Volumes of 95% ethanol, aspirated, and resuspended in
H.O.
Step 3: Ligation, Transformation and Sequencing
The plasmid designated puCFIX (See FIG. 1) containing
the modified (Kpn I ends) FIX cDNA was produced by diges
tion of both puC18 and the modified cDNA with Kpn I (per
manufacturers instructions, Stratagene, La Jolla, Calif.) puri

fication of digestion products by CHCl:Phenol (1:1) extrac
tion, precipitation with equal volumes of 95% ethanol, aspi
ration and Suspension in H2O. Ligation of plasmid and cDNA
was per manufacturers instructions (Stratagene) using 125 ng
of Kpn I digested puC18 and 125 ng of Kpn I digested
modified cDNA. E. coli JM109 was transformed by elec
troporation using ligation mixture and plated on LB amplicil
lin plates. Selected colonies were grown up in TBampicillin
broth. Plasmid preparations from these colonies were ana
lyzed by restriction enzyme digestion (Kpn I) and gel elec
trophoresis. The entire sense strand of the cDNA was
sequenced and found to be correct as compared with FIXA
sequences located in Genebank.
Step 4: Introduction of FIX cDNA into pWAP4 “cassette
vector” to produce pWAPFIX
Both pWAP4 and pUCFIX (FIG. 1) were digested with
Kpn I in separate reactions, Subjected to gel electrophoresis
and the appropriate plasmid fragments removed from the gel
and ligated. E. coli JM109 was transformed by electropora
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tion using ligation mixture and plated on LB amplicillin
plates. Selected colonies were grown up in TB amplicillin
broth. Plasmid preparations from these colonies were ana
lyzed by restriction enzyme digestion (Kpn I) then gel elec
trophoresis. Clones positive for the insert were subjected to
PCR analysis using primers FIXS1 and WAP3'A1 to deter
mine the correctorientation of the insert. The correct plasmid
is identified as pWAPFIX. The insert WAPFIX was removed
from pWAPFIX by endonuclease digestion with EcoRI, gel
purified and ligated into EcoRI digested puC18 in order to
switch the bacterial vector from pBS to puC18. The new
plasmid was designated puCWAPFIX (FIG. 2).
Step 5: Preparation of Short WAP FIX-cDNA for Micro
injection
The short WAP-FIX-cDNA (WAPFIX) construct as
described above that excised from puCWAPFIX by EcoRI
endonuclease digestion was purified for microinjection as
follows. After cleaving the construct from its vector, the solu
tion was brought to 10 mM magnesium, 20 mM EDTA and
0.1% SDS and then extracted with phenol/chloroform (1:1).
DNA was precipitated from the aqueous layer with 2.5 vol
umes of ethanol in the presence of 0.3 M sodium acetate at
-20° C. overnight. After centrifugation, the pellet was
washed with 70% ethanol, dried, and resuspended in sterile
distilled water. The extracted DNA was purified by standard
NaCl gradient ultracentrigation. DNA concentrations were
determined by agarose gel electrophoresis by staining with
ethidium bromide and comparing the fluorescent intensity of
an aliquot of the DNA with the intensity of standards.
Samples were then adjusted to 10 ug/ml and stored at -20°C.,
prior to microinjection. Unlike the examples of Clark et al.,
U.S. Pat. No. 5,714,345 and Van Cottet al., Genetic Analysis:
Biomolecular Engineering 15 (1999) 155-160, no co-injec
tion of a milk gene is done with the FIX containing construct.
Thus, no other milk protein gene that could be used to per
form “gene rescue' on the WAP5FIX construct was used; in
addition to the buffer components, the microinjection mixture
contained only the Short WAP-FIXcDNA construct DNA.
Example 2
Production of transgenic pigs that express the Short FIX
cDNA without “gene rescue' from a milk protein gene.
Step 1: Pig embryos are recovered from the oviduct and
placed into a 1.5 ml microcentrifuge tube containing approxi
mately 0.5 ml embryo transfer media (Beltsville Embryo
Culture Medium). Embryos are centrifuged for 12 minutes at
16,000xg RCF (13.450 RPM) in a microcentrifuge (Hermle,
model Z231). The embryos are then removed from the
microfuge tube with a drawn and polished Pasteur pipette and
placed into a 35mm petridish for examination. Embryos are
then placed into a microdrop of media (approximately 100 ul)
in the center of the lid of a 100 mm petridish, and silicone oil
was used to cover the microdrop and fill the lid to prevent
media from evaporating. The petri dish lid containing the
embryos is set onto an inverted microscope (Carl Zeiss)
equipped with both a heated stage and Hoffman Modulation
Contrast optics (200x final magnification). A finely drawn
(Kopf Vertical Pipette Puller, model 720) and polished (Nar
ishige microforge, model MF-35) micropipette is used to
stabilize the embryos while about 1-2 picoliters of purified
DNA solution (10 ug/ml) containing only short WAP-FIX
cDNA genetic constructs without milk proteins for cDNA
gene rescue was delivered to non-pronuclear one-cell or two
cell pig embryos using another finely drawn micropipette.
Embryos Surviving the microinjection process as judged by
morphological observation are loaded into a polypropylene
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tube (2 mm ID) for transfer into the recipient pig. About 40-50
microinjected embryos are transferred into each hormonally
synchronized Surrogate mother recipient female pig.
Step 2: Determination of transgenic piglets born from
microinjection of 1-cell and two-cell pig embryos.
The gestation time of recipient female pigs is about 114
days. About 4 to 11 piglets are born in each litter. To deter

16
human Factor IX standard derived from plasma in the TBS
BSA dilution buffer are added in triplicate to the wells (100
ul/well) and incubated at 37°C. for 30 minutes. The wells are
then washed and blocked for another 10 minutes at room

temperature. Sheep anti-human Factor 1:1000 in TBS-BSA,
is then incubated in the wells for 30 minutes at 37° C., fol

mine whether test animals carried the recombinant con

structs, tissue samples were removed from transgenic animals
and DNA isolated. DNA is isolated by digesting tissue in (50
mM Tris-HCl, 0.15 M NaCl, 1 M Na CIO 10 mM EDTA,
1% sodium dodecylsulfate, 1% 2-mercaptoethanol, 100
ug/ml proteinase K, pH 8.0). 750 ul of lysate was extracted
with 250 ul chloroform/phenol (1:1) followed by precipita
tion with isopropanol 0.7 volumes, washed in 70% ethanol
and dried. DNA is suspended in TE (10 mM Tris-HCl and 1
mM EDTA pH 8.0). Swine produced after embryo transfer of
microinjected embryos were screened by Southern analysis.
10 ug of DNA isolated from tail tissue is digested with the
endonuclease Pst Ian Subjected to agarose gel electrophoresis
and transferred to a nylon membrane. The membrane is
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probed with a P labeled DNA fragment of the WAP pro

moter consisting of the Not I to Pst I (-2.0 kbp) 5' fragment.
Hybridization is carried out at 68°C. for 4 hours using Quick
Hyb (Stratagene; LaJolla, Calif.). Following standard wash
ing methods, the membrane is Subjected to autoradiography
(-70° C.) for a period of 24 hours. Observance of a 2.0 kbp
band indicated the presence of the transgene. To confirm the
presence of the Factor IX cDNA, 10ug of DNA isolated from
tail tissue is digested with the endonuclease BamHIan Sub
jected to agarose gel electrophoresis and transferred to a

25

in TBST, blocked with TBS/0.05% Tween 20/0.5% Casein
30

nylon membrane. The membrane is probed with a Plabeled

DNA fragment of the FIX cDNA consisting of the whole
cDNA Kpn I to Kpn I (~1.4 kbp). Hybridization is carried out
at 68°C. for 4 hours using Quick Hyb (Stratagene; LaJolla,
Calif.). Following standard washing methods, the membrane
is subjected to autoradiography (-70° C.) for a period of 24
hours. Observance of a ~5.5 kbp band indicates the presence
of the short WAP-FIX-cDNA transgene.
Step 3: Collection and storage of milk from transgenic pigs
containing short WAP-FIX-cDNA without “gene rescue'
from a milk protein gene.
Lactating sows are injected intramuscularly with 30-60 IU
of oxytocin (Vedco Inc., St. Joseph, Mo.) to stimulate milk
let-down. Letdown occurs two to five minutes after injection.
Pigs are milked by hand during the course of this study.
Immediately after collection the milk is diluted 1:1 with 200
mM EDTA, pH 7.0 to solubilize the caseins and then frozen.
Small aliquots (about one milliliter) of the milk/EDTA mix
ture are taken and centrifuged for approximately 30 minutes
at 16000xg at 4°C. The fat layer is separated from the diluted
whey fraction, and the diluted whey fraction is used for all
further assays.
Step 4: Detection of high levels of recombinant human FIX
in milk of transgenic pigs containing short WAP-FIX-cDNA
without the use of "gene rescue' from a milk protein gene.
Data from milk samples that are processed to diluted whey
samples are interpreted multiplied by a factor of 1.9 to
account for dilution with EDTA and subsequent removal of
milk fat. Amounts of Factor IX in milk are measured by
polyclonal ELISA. Briefly, Immulon II microtiter plates
(Fisher Scientific, Pittsburgh) are coated overnight with 100
ul/well of 1:1000 rabbit anti-human Factor IX (Dako) in 0.1
M. NaHCO, 0.1 M NaCl, pH 9.6 at 4°C. The wells are
washed with TBS-Tween (TBST, 25 mM Tris, 50 mM NaCl,
0.2% Tween 20, pH 7.2), and then blocked for 30 minutes
with TBS/0.1% BSA at room temperature. Samples and

lowed by anti-sheep IgG/HRP (Sigma, St. Louis). Bound
chromophore is detected with OPD substrate (Abbott, Chi
cago) at 490 nm using an EL308 Bio-Tek Microplate reader.
Daily expression levels of FIX are about 100-500 g/ml milk
and this is maintained throughout 50-60 day lactation.
Step 5: Western analysis of the high level expression of
recombinant human FIXinmilk of transgenic pigs containing
short WAP-FIX-cDNA without the use of “gene rescue” from
a milk protein gene.
Recombinant human Factor IX (rhFIX) also is examined
using Western Blot Analysis. Daily samples of EDTA-diluted
whey as prepared above and taken from transgenic short
WAP-FIXcDNA pigs are electrophoresed on 8-16% SDS gels
(Novex, San Diego). Approximately 125 ng of recombinant
human Factor IX (as determined by polyclonal ELISA) and
human Factor IX standard derived from plasma are loaded in
each lane. A total of 25 ug of total protein from a pool of
non-transgenic (NTG) whey is loaded on the gels. After elec
trophoresis, proteins are transferred overnight to PVDF mem
branes (Bio Rad). The membranes are washed for 30 minutes
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(TBST-Casein). The membranes are developed with rabbit
anti-Factor IX (Dako) (1:1000 in TBST-Casein for 45 min
utes at 37° C.), followed by anti-rabbit IgG/HRP (Sigma)
(1:1000 in TBST-Casein for 45 minutes at 37° C.), and the
DAB metal enhanced staining (Pierce). Molecular weight
markers are purchased from Bio-Rad. The presence of about
100-500 ug/ml of rhFIX in the milk of transgenic pigs con
taining the short WAP-FIX-cDNA without benefit of the gene
rescue by a milk protein gene is detected by the Western Blot
Analysis.
Example 3
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Purification of high levels of recombinant human FIX
(rhFIX) in milk of transgenic pigs containing short WAP
FIX-cDNA having achieved high expression of rhEIX with
out the use of "gene rescue' from a milk protein gene.
Recombinant human Factor IX is purified from whey
derived from a pool consisting of milk taken from 50-60 days
of the first lactation of a short WAP-FIX-cDNA transgenic
pig. The first step consisted of ion exchange chromatography
followed by metal-dependent immunoaffinity chromatogra
phy using a monoclonal antibody designated as MAb1 H5. In
these studies, all columns and buffers are kept at 4°C. A pool
of daily EDTA-expanded whey samples is diluted to OD 280
um of 5.0 with TBS, pH 7.2, then loaded at 1 cm/min on
DEAE FF Sepharose. The column is washed with TBS, pH
7.2, and then eluted with 0.25 MNaCl in TBS. This fraction

is diluted 1:1 with 40 mM MgCl, in TBS to a final concen
tration of 20 mM MgCl2 and loaded on a 1H5 MAb column.
The column is washed with TBS containing 20 mM MgCl,
and the product is eluted with 20 mM citrate, 0.15 M NaCl,
pH 6.8. The product is dialyzed overnight against 10 mM
imidazole, pH 7.2.
Example 4
Determination of the biological activity of immunopurified
recombinant Human Factor IX (rhFIX) processed from milk
of transgenic pigs containing short WAP-FIX-cDNA having
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achieved high level expression of rhFIX without using “gene
rescue' from a milk protein gene.
The biological activity of the purified recombinant human
Factor IX from a transgenic pig is measured using a one-stage
activated partial thromboplastin clotting time assay (APTT)
clotting assay following a protocol given by the American
Red Cross Plasma Derivatives Laboratory (Procedure for
Factor IX Coagulation Assay, March 1992). Briefly, each well
of a plastic Coag-a-mate tray receives 90 ul of Factor IX
deficient plasma plus 10ul of a Factor IX standard or sample,
diluted with Tris/saline/BSA. The tray is then placed on an
automated analyzer (APTT mode, 240 second activation).
The run is started, which automatically performed the addi
tion of 100 ul of APTT reagent and 100 ul of 0.025 M CaCl.
Data obtained using a standard Factor IX preparation are
fitted to the equation y-ax+b where y-clotting time and

18
The lyophilized powder of example 5 is reconstituted with
aqueous containing ordinary bovine milk cream Such as to
restore the volume to 25 to 50-fold concentrate over that of the

original whey. The mixture is fed to hemophilia type B mice
shortly after their first meal post sleep where less than 1 ml is
fed to each mouse. The bleeding time by measured tail inci
sion is measured 12 hours later. The corrected bleeding time
is 5-7 minutes as compared to 11 minutes for a control hemo
philiac mouse who was not fed the rhFIX milk concentrate
10

Example 7
15

X-Factor IX, which is then used to determine the amount of

Factor IX in a sample. The Standards of normal plasma ref
erence pool (Sigma) and human Factor IX derived from
plasma are used in the assay. Duplicates of the immunopuri
normal plasma reference pool samples are run at each dilu
tion. The immunopurified recombinant human Factor IX had
a specific activity of about 200-350 U/mg, which is compa
rable to the immunopurified human Factor IX from plasma
which had a specific activity of 200-230 U/mg, with the
normal plasma reference pool activity being defined as 250
U/mg.
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Example 5

30

A milk derivative of a recombinant Human Factor IX
35

exchange columnusing 15 mM Ca"Tris-buffered-saline 150

mM NaCl (TBS). This eluted fraction of rhFIX containing
selected, highly biologically active fractions of rhPIX is use
ful for oral delivery of rhPIX for therapeutic treatment of
hemophilia B patients is passed through a 0.2 micron filter top
remove bacterial contamination and then lyophilized to a
powder. The rhFIX in the DEAE-column eluate has a com
position that is volume reduced and concentrated by 25 to
50-fold over that of starting skim milk.
Example 6
A therapeutic application achieving oral delivery of the
recombinant Human Factor IX (rhFIX) using a milk deriva
tive made from the milk of transgenic pigs containing short
WAP-FIX-cDNA having high level expression of rhFIX
achieved without using "gene rescue' from a milk protein
gene.

Mice are fed the reconstituted mixture from example 6
everyday consecutively for one month and after this month,
they are sensitized with complete Freund's adjuvant and
recombinant human Factor IX. After 12 days, blood samples
from these mice do not respond with the presence of anti
human FIX antibodies and also does not respond with T-cells
which are activated by the presence of recombinant FIX
derived from Chinese Hamster ovary cells. Control mice that
have not been fed the mixture from example 12 are sensitized
with the same adjuvant and human FIX mixture. After 12-14
days the blood of these human FIX sensitized control mice
exhibit a strong immunological response consisting of both
anti-human FIX antibodies and T-cells that are activated by
the presence of human FIX.
Example 8

A milk derivative concentrate of recombinant human FIX

(rhFIX) useful for oral delivery of rhFIX is made from the
milk of a transgenic pig containing a transgene composed of
the 2.5 kbp mouse whey acidic protein promoter (WAP), the
cDNA encoding human FIX, and a 1.6 kbp fragment of the 3'
UTR of WAP. The expression level is about 0.1-0.5 g/l of
rhFIX. Greater than about 80% of the rhFIX is biologically
active. The skim milk is treated with a chelating agent Such as
100 mM EDTA pH 7.5 or 100 mM Sodium Citrate pH 6.5 to
clarify the milk of casein micelles. The clarified whey is
passed over a DEAE-Sepharose or DEAE-Cellulose chro
matographic column and the rhFIX is adsorbed. This
adsorbed rhFIX is selectively desorbed from the anion

A therapeutic application achieving oral immunotoleriza
tion of recombinant Human Factor IX (rhFIX) derived from
Chinese Hamster Ovary cells using a milk derivative contain
ing rhFIX made from milk of transgenic pigs containing short
WAP-FIX-cDNA having high level expression of rhFIX
achieved without using "gene rescue' from a milk protein
gene.

fied recombinant human Factor IX, human Factor IX, and

(rhEIX) processed from milk of transgenic pigs containing
short WAP-FIX-cDNA having high level expression of rhFIX
achieved without using "gene rescue' from a milk gene.

and 5 minutes for a normal mouse with normal hemostasis.
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A therapeutic application achieving oral immunotoleriza
tion of recombinant Human Factor IX (rhFIX) using a milk
derivative having the same rhFIX that is made from milk of
transgenic pigs containing short WAP-FIX-cDNA having
high level expression of rhFIX achieved without using “gene
rescue' from a milk protein gene.
Mice are fed the reconstituted mixture from example 6
everyday consecutively for one month and after this month,
they are sensitized with complete Freund's adjuvant and
recombinant human Factor IX. After 12 days, blood samples
from these mice do not respond with the presence of anti
human FIX antibodies and also do not respond with T-cells
which are activated by the presence of recombinant FIX
derived from the milk of transgenic pigs. Control mice that
have not been fed the mixture from example 12 are sensitized
with the same adjuvant and human FIX mixture. After 12-14
days the blood of these human FIX sensitized control mice
exhibit a strong immunological response consisting of both
anti-human FIX antibodies and T-cells that are activated by
the presence of human FIX.
Example 9
A therapeutic application achieving oral immunotoleriza
tion of Human Factor IX derived from plasma using a milk
derivative containing rhFIX made from milk of transgenic
pigs containing short WAP-FIX-cINA having high level
expression of rhFIX achieved without using “gene rescue'
from a milk protein gene.
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Mice are fed the reconstituted mixture from example 6
everyday consecutively for one month and after this month,
they are sensitized with complete Freund's adjuvant and
recombinant human Factor IX. After 12 days, blood samples
from these mice do not respond with the presence of anti
human FIX antibodies and also do not respond with T-cells
which are activated by the presence of human FIX. Control
mice that have not been fed the mixture from example 12 are
sensitized with the same adjuvant and human FIX mixture.
After 12-14 days the blood of these human FIX sensitized
control mice exhibit a strong immunological response con
sisting of both anti-human FIX antibodies and T-cells that are
activated by the presence of human FIX.
Example 10
Construction and preparation of the 4.1 kb WAP driven
FIX-cDNA (long WAP-FIX-cDNA) construct
for microinjection into embryos to make transgenic ani
mals having high level expression of FIX achieved without
using "gene rescue” from a milk gene.
Step 1: Generally, the entire murine WAP gene was cloned
by standard methods, as described above in Example 1, and
the regulatory 5' and 3' UTR-flanking sequences of the mouse
WAP gene were used for mammary specific expression (Gift
from Lothar Hennighausen NIH). Specifically, a cassette vec
tor (pUCWAP6) containing a “long WAP promoter, defined
as a 4.1 kbp Not I-Kpn I fragment immediately 5' to the WAP
signal sequence and a 1.6 kbp fragment of the 3' untranslated
region of the WAP gene was prepared. These regulatory
sequences do not include coding and intragenic untranslated
sequences (introns) of the mWAP gene. The development of
pUCWAP6 was as follows: The puC18 vector (Invitrogen)
was cut with the enzymes EcoRI and HindIII to remove the
multiple cloning site of the vector, blunted with exonuclease
and ligated with Not I linkers. The plasmid was then cut with
Not I and ligated. Ligation mixture was used to transform E.
coli DH5C. cells on LB ampicillin plates, picked colonies
were grown in TB ampicillin broth, plasmids were isolated
and cut with Not I then subjected to gel electrophoresis.
Plasmid was judged to be correct and designated as puCNotI
(See FIG. 3). The vector pWAP4 (described above) was
digested with EcoRI and the fragment containing the WAP
5'-2.5 kbp promoter and 3'-UTR genetic elements were sepa
rated by gel electrophoresis and purified. The ends of the
fragment were modified by blunting with exonuclease and
Not I linkers were ligated on. The fragment was cut with Not
I and ligated into the Not I restriction site of pUCNotI then
used to transform E. coli DH5C. cells on ampicillin plates.
Picked colonies were grown in TB ampicillin broth. The
Isolated plasmid was verified to be correct by Not I digestion
with the plasmid being designated puCWAP5. The puC
WAP5 plasmid was subjected to Kpn I digestion and a partial
Not I digestion producing a fragment that contained the puC
NotI vector sequence flanked by the mWAP 3'-UTR. This
fragment was ligated with the 4.1 kb 5’-WAP promoter pro
duced from digestion of p227.6 (gift from American Red
Cross) with NotI, KipnI and HindIII. The ligation mixture was
then used to transform E. coli JM109 cells that were grown on
LBampicillin plates picked colonies were grown in TBampi
cillin broth, plasmids isolated were cut with Not I, and NotI/
KpnI and judged to be correct. The plasmid was then desig
nated puCWAP6 (See FIG. 4).
Step 2: Production of puCWAP6FIX
The plasmid puCWAP6FIX was produced by digestion of
pUCWAPFIX with Kpn I and isolating the FIX cDNA by gel
electrophoresis. This fragment was purified using a gel
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extraction kit (Qiagen; Valencia, Calif.) and inserted into the
KpnI site of pUCWAP6 after Kipn I digestion and both frag
ments were then Subjected to ligation. The ligation mixture
was then used to transform E. coli JM109 cells that were then

plated on LBampicillin plates. Picked colonies were grown in
TB amplicillin broth and plasmids were isolated. Isolated
plasmids were digested with Nsi I to verify orientation of the
cDNA insert. Plasmids that contained the insert in the correct
10

orientation were designated puCWAP6FIX. After insert con
firmation, large scale purification was undertaken, according
to methods well known in the art. This is termed the “long
WAP-FIX-cDNA.
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Step 3: Preparation of Long WAP-FIX-cDNA for Micro
injection
The Long WAP-FIX-cDNA constructed as described in the
above in steps was excised from puCWAP6FIX by Not I
endonuclease digestion and purified for microinjection as
follows. After cleaving a WAP6FIX from its vector, DNA was
purified by standard NaCl gradient ultracentrigation. DNA
concentrations were determined by agarose gel electrophore
sis by staining with ethidium bromide and comparing the
fluorescent intensity of an aliquot of the DNA with the inten
sity of standards. Samples were then adjusted to 10 ug/ml and
stored at -20° C., prior to microinjection. No other milk
protein gene that could be used to perform gene rescue for this
Long WAP-FIXcDNA construct was used; in addition to the
buffer components, the microinjection mixture contained
only the Long WAP-FIXcDNA construct DNA.
Example 11

Production of Long WAP-FIX-cDNA transgenic micehav
ing high level expression of rhEIX achieved without using
'gene rescue' from a milk gene.
Step 1: Transgenic mice were produced essentially as
described by Hogan et al., Manipulating the Mouse Embryo,
Cold Spring Harbor Press, (1986), which is hereby incorpo
rated by reference. That is, glass needles for micro-injection
were prepared using a micropipet puller and microforge.
Injections were performed using a Nikon microscope having
Hoffman Modulation Contrast optics, with Narashigi micro
manipulators and a pico-injector driven by N2 (Narashigi).
Fertilized mouse embryos were surgically removed from ovi
ducts of superovulated female CD-1 mice and placed into M2
medium. Cumulus cells were removed from the embryos with
hyaluronidase at 300 ug/ml. The embryos were then rinsed in
new M2 medium, and stored at 37 degrees centigrade prior to
injection. Stock Solutions containing about 5 g/ml of the
above described DNA were prepared and microinjected into
non-pronuclear mouse embryos. After injecting the DNA,
embryos were implanted into avertin-anesthesized CD-1
recipient females made pseudo-pregnant by mating with
vasectomized males. About 25-30 microinjected mouse
embryos per recipient were transferred into pseudopregnant
females.

Step 2: DNA was isolated by digesting tissue in (50 mM
Tris-HCl, 0.15 M NaCl, 1 M NaClO 10 mM EDTA, 1%
sodium dodecylsulfate, 1% 2-mercaptoethanol, 100 ug/ml
proteinase K. pH 8.0). 750 ul of lysate was extracted with 250
ul chloroform/phenol (1:1) followed by precipitation with
isopropanol 0.7 volumes, washed in 70% ethanol and dried.
DNA was suspended in TE (10 mM Tris-HCl and 1 mM
EDTA pH 8.0). Mice produced after embryo transfer of
microinjected embryos were screened by Southern analysis.
To confirm the presence of the Factor IX cDNA. 10 ug of
DNA isolated from tail tissue was digested with the endonu
clease BamHIan Subjected to agarose gel electrophoresis and
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transferred to a nylon membrane. The membrane was probed

with a Plabeled DNA fragment of the FIXcDNA consisting

of the whole cDNA Kpn I to Kpn I (~1.4 kbp). Hybridization
was carried out at 68°C. for 4 hours using Quick Hyb (Strat
agene; LaJolla, Calif.). Following standard washing methods,
the membrane was subjected to autoradiography (-70°C.) for
a period of 24 hours. Observance of a ~7.1 kbp band indicated
the presence of the whole transgene.
Example 12
Western Analysis of high level expression of recombinant
human FIX in milk of transgenic mice containing long WAP
FIX-cDNA achieved without using gene rescue from a milk
protein gene.
Recombinant human Factor IX from the milk of transgenic
mice having the long WAP-FIX-cDNA (without gene rescue
from a milk protein gene) was examined using Western analy
sis. Daily samples of EDTA-diluted whey as prepared above
and taken from transgenic short WAP-FIXcDNA pigs were
electrophoresed on 8-16% SDS gels (Novex, San Diego).
Approximately 125 ng of recombinant human Factor IX (as
determined by polyclonal ELISA) and human Factor IX stan
dard derived from plasma were loaded in each lane. A total of
25 ug of total protein from a pool of non-transgenic (NTG)
whey was loaded on the gels. After electrophoresis, proteins
were transferred overnight to PVDF membranes (Bio Rad).
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nylon membrane. The membrane was probed with a P
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The membranes were washed for 30 minutes in TBST,

blocked with TBS/0.05% Tween 20/0.5% Casein (TBST
Casein). The membranes were developed with rabbit anti
Factor IX (Dako) (1:1000 in TBSTCasein for 45 minutes at
37° C), followed by anti-rabbit IgG/HRP (Sigma) (1:1000 in
TBST-Casein for 45 minutes at 37° C.), and the DAB metal
enhanced staining (Pierce). Molecular weight markers were
purchased from Bio Rad. Western analyses revealed the pres
ence of three Sub-populations of recombinant human Factor
IX in transgenic mouse derived samples: the major popula
tion migrated at a M, of about 60-65 kDa, which is a slightly
lower M, than human Factor IX, and minor sub-populations
migrated at about 40-45 kDa, and at about 25 kDa. Plasma
human Factor IX also possessed a subpopulation at about
45-50 kDa. The transgenic mouse milk samples were esti
mated to contain about 1 to 2 g/l of rhFIX.
Example 13
Production of transgenic pigs that express the long WAP
FIX-cDNA at very high levels achieved without using “gene
rescue' from a milk protein gene.
Step 1: Pig embryos were recovered from the oviduct, and
were placed into a 1.5 ml microcentrifuge tube containing
approximately 0.5 ml embryo transfer media (Beltsville
Embryo Culture Medium). Embryos were centrifuged for 12
minutes at 16,000xg RCF (13.450 RPM) in a microcentrifuge
(Hermle, model Z231). The embryos were then removed
from the microcentrifuge tube with a drawn and polished
Pasteur pipette and placed into a 35 mm petridish for exami
nation. Embryos were then placed into a microdrop of media
(approximately 100 ul) in the center of the lid of a 100 mm
petri dish, and silicone oil was used to cover the microdrop
and fill the lid to prevent media from evaporating. The petri
dish lid containing the embryos was set onto an inverted
microscope (Carl Zeiss) equipped with both a heated Stage
and Hoffman Modulation Contrast optics (200x final magni
fication). A finely drawn (Kopf Vertical Pipette Puller, model
720) and polished (Narishige microforge, model MF-35)
micropipette was used to stabilize the embryos while about
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1-2 picoliters of stock solution containing about 10 g/ml of
the above described DNA was microinjected into the non
pronuclear stage pig embryos using another finely drawn
micropipette. Embryos Surviving the microinjection process
as judged by morphological observation were loaded into a
polypropylene tube (2 nun ID) for transfer into the recipient
pig. About 40-50 microinjected embryos were transferred
into each hormonally synchronized Surrogate mother recipi
ent female pig.
Step 2: Determination of transgenic piglets born from
microinjection of pig embryos.
DNA was isolated by digesting tissue in (50 mM Tris-HCl,
0.15 M NaCl, I M Na CIO 10 mM EDTA, 1% sodium
dodecylsulfate, 1% 2-mercaptoethanol, 100 ug/ml proteinase
K, pH 8.0). 750 ul of lysate was extracted with 250 ulchlo
roform/phenol (1:1) followed by precipitation with isopro
panol 0.7 volumes, washed in 70% ethanol and dried. DNA
was suspended in TE (10 mM Tris-HCl and 1 mM EDTA pH
8.0). Pigs produced after embryo transfer of microinjected
embryos were screened by Southern analysis. To confirm the
presence of the Factor IX clNA. 10 ug DNA isolated from
tail tissue was digested with the endonuclease BamHI an
Subjected to agarose gel electrophoresis and transferred to a
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labeled DNA fragment of the FIX clNA consisting of the
whole cDNA Kpn I to Kpn I (~1.4 kbp). Hybridization was
carried out at 68°C. for 4 hours using Quick Hyb (Stratagene:
LaJolla, Calif.). Following standard washing methods, the
membrane was subjected to autoradiography (-70° C.) for a
period of 24 hours. Observance of a ~7.1 kbp band indicated
the presence of the entire long WAP-FIX-cINA transgene.
Step 3: Collection and storage of milk from transgenic pigs
containing Long WAP-FIX-cDNA without using “gene res
cue' by a milk protein gene.
Lactating sows were injected intramuscularly with 30-60
IU of oxytocin (Vedco Inc., St. Joseph, Mo.) to stimulate milk
let-down. Letdown occurred two to five minutes after injec
tion. Pigs were milked by hand during the course of this study.
Immediately after collection the milk was diluted 1:1 with
200 mM EDTA, pH 7.0 to solubilize the caseins and then
frozen. Small aliquots (about one milliliter) of the milk/
EDTA mixture were taken and centrifuged for approximately
30 minutes at 16000xg at 4°C. The fat layer was separated
from the diluted whey fraction, and the diluted whey fraction
was used for all further assays.
Step 4: Detection of recombinant human fix in milk of
transgenic pigs containing Long WAP-FIX-cINA without
using "gene rescue' by a milk protein gene.
Data from milk samples that were processed to diluted
whey samples were adjusted by a factor of 1.9 to account for
dilution with EDTA and subsequent removal of milk fat.
Amounts of Factor IX in milk were measured by polyclonal
ELISA. Briefly, Immulon II microtiter plates (Fisher Scien
tific, Pittsburgh) were coated overnight with 100 ul/well of
1:1000 rabbit anti-human Factor IX (Dako) in 0.1 M
NaHCO, 0.1 MNaCl, pH 9.6 at 4°C. The wells were washed
with TBS-Tween (TBST, 25 mM Tris, 50 mM NaCl, 0.2%
Tween 20, pH 7.2), and then blocked for 30 minutes with
TBS/0.1% BSA at room temperature. Samples and human
Factor IX standard derived from plasma in the TBS-BSA
dilution buffer were added in triplicate to the wells (100
ul/well) and incubated at 37° C. for 30 minutes. The wells

were thenwashed and blocked for another 10 minutes at room

temperature. Sheep anti-human Factor IX 1:1000 in TBS
65

BSA, was then incubated in the wells for 30 minutes at 37°C.,

followed by anti-sheep IgG/HRP (Sigma, St. Louis). Bound
chromophore was detected with OPD substrate (Abbott, Chi
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cago) at 490 nm using an EL308 Bio-Tek Microplate reader.
Daily expression levels of about 2000-5000 ug/ml milk were
maintained throughout 50-60 day lactation.
Step 5: Western analysis of high level expression of recom
binant human FIX (rhFIX) in milk of transgenic pigs contain
ing long WAP-FIX-cDNA without using “gene rescue' by a
milk protein gene.
Recombinant human Factor IX also was examined using
Western analysis. Daily samples of EDTA-diluted whey as
prepared above and taken from transgenic Long WAP-FIX
cDNA pigs were electrophoresed on 8-16% SDS gels
(Novex, San Diego). Approximately 125 ng of recombinant
human Factor IX (as determined by polyclonal ELISA) and
human Factor IX standard derived from plasma were loaded
in each lane. A total of 25 ug of total protein from a pool of
non-transgenic (NTG) whey was loaded on the gels. After
electrophoresis, proteins were transferred overnight to PVDF
membranes (Bio Rad). The membranes were washed for 30
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Example 15

5

gene.
10
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minutes in TBST, blocked with TBS/0.05% Tween 20/0.5%

Casein (TBST-Casein). The membranes were developed with
rabbit anti-Factor IX (Dako) (1:1000 in TBST-Casein for 45
minutes at 37°C.), followed by anti-rabbit IgG/HRP (Sigma)
(1:1000 in TBST-Casein for 45 minutes at 37° C.), and the
DAB metal enhanced staining (Pierce). Molecular weight
markers were purchased from Bio Rad. Western analyses
revealed the presence of three sub-populations of recombi
nant human Factor IX: the major population migrated at a M.
of about 60-65 kDa, which is a slightly lower M, than human
Factor IX, and minor Sub-populations migrated at about
40-45 kDa, and at about 25 kDa. Plasma human Factor IX
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also possessed a subpopulation at about 45-50 kDa. The con
centration of rhFIX in milk was estimated to be about 2 g/l or
35

sample. Standards of normal plasma reference pool (Sigma)
and human Factor IX derived from plasma are used in the
assay. Duplicates of purified recombinant human Factor IX,
human Factor IX, and normal plasma reference pool samples

are run at each dilution. TherhPIX in the 5 mM Ca" aspecific
activity of about 150-250 u/mg. The rhFIX in the 10 mM Ca"
rhFIX in the 2 MNaCl gives a specific activity of less than 25
u/mg. The specific activity of the rhFIX of normal plasma
reference pool is defined as 250 u/mg where the overall activ
ity of the pool is 1 u/ml while containing 4 ug/ml of rhFIX.
Example 16
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A milk derivative containing recombinant Human Factor
IX processed from milk of transgenic pigs containing Long
WAP-FIX-cDNA having high level expression of rhFIX
achieved without using "gene rescue' from a milk protein
gene.
A milk derivative concentrate of recombinant Human FIX

Q-Sepharoseanion exchange matrix by Ca"-specific elution.

In these studies, all columns and buffers were kept at 4°C. A
pool of daily EDTA-expanded whey samples was diluted to
OD 280 nm of 5.0 with TBS, pH 7.2, then loaded at 1 cm/min
on DEAEFF Sepharose. The column was washed with TBS,
pH 7.2, and then eluted with 0.25 MNaCl in TBS. The rhFIX
was eluted from the DEAE-Sepharose using 300 mMNaCl in
TBS. This rhFIX containing eluate was dialyzed to TBS and
loaded onto Q-Sepharose. The rhFIX was eluted from the

which is then used to determine the amount of Factor IX in a

a specific activity of about 100 u/mg or less. TheFIX in the 15

Purification of recombinant human FIX in milk of trans

genic pigs containing Long WAP-FIX-cDNA having high
level expression of FIX achieved without using “gene rescue'
from a milk gene.
Recombinant human Factor IX (rhFIX) was purified from
whey derived from a pool consisting of milk taken from 50-60
days of the first lactation of a Long WAP-FIX-cDNA trans
genic pig. The first step consisted of DEAE exchange chro
matography, followed by hydrophobic interaction chroma
tography, followed by chromatographic adsorption onto

The biological activity of the recombinant human Factor
IX purified from the milk of Long WAP-FIX-cDNA pigs
described in Example 14 is measured using a one-stage acti
vated partial thromboplastin clotting time assay (APTT) clot
ting assay following a protocol given by the American Red
Cross Plasma Derivatives Laboratory (Procedure for Factor
IX Coagulation Assay, March 1992). Briefly, each well of a
plastic Coag-a-mate tray received 90 ul of Factor IX-deficient
plasma plus 10 ul of a Factor IX standard or sample, diluted
with Tris/saline/BSA. The tray was then placed on an auto
mated analyzer (APTT mode, 240 second activation). The run
is started, which automatically performed the addition of 100
ul of APTT reagent and 100 ul of 0.025 M CaCl. Data
obtained using a standard Factor IX preparation are fitted to
the equation y-ax+b where y-clotting time and X-Factor IX,

mM Ca" a specific activity of less than about 50 u/mg. The

O.

Example 14

Determination of the biological activity of purified rhFIX
processed from milk of transgenic pigs containing Long
WAP-FIX-cDNA having high level expression of FIX
achieved without using "gene rescue' from a milk protein
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Q-Sepharose column using 15 mM CaCl (Ca") in TBS. The

rhFIX containing eluate from the Q-Sepharose eluate was
rendered 1 M NaCl. The rhFIX passes through the Butyl

column unabsorbed. The unabsorbed material from the

Butyl-Sepharose column containing the rhFIX is dialyzed
against TBS to remove the majority of casein milk protein
contaminants. The dialyzed rhFIX containing fraction in TBS
is adsorbed to Q-Sephrose and eluted in a sequence of 5 mM

60

buffers. The chromatographic procedure isolated in these
fractions contained rhFIX to about 80% or higher purity as
judged by silver-stained SDS-PAGE.

65

Ca", 10 mM Ca", 15 mM Ca", and 2 M NaCl in TBS

useful for oral delivery of rhFIX is made from the milk of a
transgenic pig containing a transgene composed of the 2.5
kbp mouse whey acidic protein promoter (WAP), the cDNA
encoding human FIX, and a 1.6 kbp fragment of the 3'UTR of
WAP. The expression level is about 0.1-0.5 g/l of rhFIX.
Greater than about 80% of the rhFIX is biologically active.
The skim milk is treated with a chelating agent such as 100
mM EDTA pH 7.5 or 100 mM Sodium Citrate pH 6.5 to
clarify the milk of casein micelles. The clarified whey is
passed over a DEAE-Sepharose or DEAE-Cellulose chro
matographic column and the rhFIX is adsorbed. This
adsorbed rhFIX is selectively desorbed from the anion

exchange column using 5 mM Ca" Tris-buffered-saline 150

mM NaCl (TBS). This eluted fraction of rhFIX containing
selected, highly biologically active fractions of rhPIX is use
ful for oral delivery of rhFIX for therapeutic treatment of
hemophilia B patients is pass through a 0.2 micron filter top
remove bacterial contamination and then lyophilized to a
powder. The rhFIX in the DEAE-column eluate has a com
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position that is volume reduced and concentrated by 25 to
50-fold over that of starting skim milk.
Example 17
A therapeutic application achieving oral delivery of the
recombinant Human Factor IX using a milk derivative made
from the milk of transgenic pigs containing Long WAP-FIX
cDNA having high level expression of rhFIX achieved with
out using "gene rescue' from a milk protein gene.
The lyophilized powder of example 5 is reconstituted with
aqueous containing ordinary bovine milk cream Such as to

26
Example 20

10

restore the volume to 25 to 50-fold concentrate over that of the

original whey. The mixture is fed to hemophilia type B mice
shortly after their first meal post sleep where less than 1 ml is
fed to each mouse. The bleeding time by measured tail inci
sion is measured 12 hours later. The corrected bleeding time
is 5-7 minutes as compared to 11 minutes for a control hemo
philiac mouse who was not fed the rhFIX milk concentrate

15

FIX. Control mice that have not been fed the mixture from

example 16 are sensitized with the same adjuvant and human
FIX mixture. After 12-14 days the blood of these human FIX
sensitized control mice exhibit a strong immunological
response consisting of both anti-human FIX antibodies and
T-cells that are activated by the presence of human FIX
derived from plasma.

and 5 minutes for a normal mouse with normal hemostasis.

Example 18
A therapeutic application achieving oral immunotoleriza
tion of recombinant Human Factor IX derived from Chinese

Hamster Ovary cells using a milk derivative containing
recombinant FIX made from milk of transgenic pigs contain
ing Long WAP-FIX-cDNA having high level expression of
rhFIX achieved without using “gene rescue” from a milk
protein gene.
Mice are fed the reconstituted mixture from example 16 for
everyday consecutively for one month and after this month,
they are sensitized with complete Freund's adjuvant and
recombinant human Factor IX. After 12 days, blood samples
from these mice do not respond with the presence of anti
human FIX antibodies and also does not respond with T-cells
which are activated by the presence of recombinant FIX
derived from Chinese Hamster ovary cells. Control mice that
have not been fed the mixture from example 16 are sensitized
with the same adjuvant and human FIX mixture. After 12-14
days the blood of these human FIX sensitized control mice
exhibit a strong immunological response consisting of both
anti-human FIX antibodies and T-cells that are activated by
the presence of human FIX.

25

30

35

40

45

A therapeutic application achieving oral immunotoleriza
tion of recombinant Human Factor IX derived from cell cul
50

55

FIX useful for oral delivery to a patient comprising a biologi
cally active Factor IX derived from milk produced by a trans
genic pig whose genome comprises a stably integrated exog
enous DNA molecule encoding human Factor IX, wherein
said human Factor IX was purified and concentrated over the
Factor IX present in said milk of said transgenic pig, and
mixed with a pharmaceutically acceptable carrier to form said
milk derivative concentrate comprising a dose for oral deliv
ery from 2.5 mg/ml to 250 mg/ml of Factor IX.
2. The milk derivative concentrate according to claim 1,
wherein said purified human Factor IX was lyophilized to a
powder prior to mixing with said carrier.
3. The milk derivative concentrate according to claim 1,
4. The milk derivative concentrate according to claim 1,
wherein said human Factor IX was purified via chromatog
raphy.
5. The milk derivative concentrate according to claim 1,
wherein said human Factor IX comprises a specific activity of

about 150-250 U/mg in 5 mM Ca".

6. A method of treating a patient having hemophilia B
comprising orally administering to said patient a hemophilia
B symptom preventing or ameliorating amount of a milk
derivative concentrate of recombinant human FIX compris
ing a biologically active Factor IX derived from milk pro
duced by a transgenic pig whose genome comprises a stably
integrated exogenous DNA molecule encoding human Factor
IX, wherein said human Factor IX was purified and concen
trated over the Factor IX present in said milk of said trans
genic pig, and mixed with a pharmaceutically acceptable
carrier to form said milk derivative concentrate, wherein said

recombinant human Factor IX derived from Chinese Hamster

Ovary cells. After 12 days, blood samples from these mice do
not respond with the presence of anti-human FIX antibodies
and also does not respond with T-cells which are activated by
the presence of recombinant FIX derived from the milk of
transgenic pigs. Control mice that have not been fed the
mixture from example 16 are sensitized with the same adju
vant and rhFIX mixture. After 12-14 days the blood of these
human FIX sensitized control mice exhibit a strong immuno
logical response consisting of both anti-human FIX antibod
ies and T-cells that are activated by the presence of rhFIX.

What is claimed is:
1. A milk derivative concentrate of recombinant human

wherein said carrier is milk or a milk derivative.

Example 19

ture by using a milk derivative containing recombinant FIX
made from milk of transgenic pigs containing Long WAP
FIX-cDNA having high level expression of FIX achieved
without using "gene rescue' from a milk gene.
Mice are fed the reconstituted mixture from example 16 for
everyday consecutively for one month and after this month,
they are sensitized with complete Freund's adjuvant and

A therapeutic application achieving oral immunotoleriza
tion of Human Factor IX derived from plasma by using a milk
derivative containing recombinant FIX made from milk of
transgenic pigs containing Long WAP-FIX-cDNA having
high level expression of rhFIX achieved without using “gene
rescue' from a milk protein gene.
Mice are fed the reconstituted mixture from example 16
everyday consecutively for one month and after this month,
they are sensitized with complete Freund's adjuvant and
recombinant human Factor IX. After 12 days, blood samples
from these mice do not respond with the presence of anti
human FIX antibodies and also does not respond with T-cells
which are activated by the presence of recombinant or human

60

amount of orally administered Factor IX comprises from 2.5
mg/ml to 250 mg/ml of Factor IX, and results in reduced
bleeding time in said patient as compared to no administra
tion of Factor IX to said patient, achieving atherapeutic effect
in treating hemophilia B and achieving oral immunotoleriza
tion of said Factor IX.

7. The method according to claim 6, wherein said purified
human Factor IX was lyophilized to a powderprior to mixing
65

with said carrier.

8. The method according to claim 6, wherein said carrier is
milk or a milk derivative.
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9. The method according to claim 6, wherein said human
Factor IX was purified via chromatography.
10. The method according to claim 6, wherein said human
Factor IX comprises a specific activity of about 150-250
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13. The method according to claim 12, wherein said puri
fied human Factor IX was lyophilized to a powder prior to
mixing with said carrier.
14. The method according to claim 12, wherein said carrier

U/mg in 5 mM Ca".

11. The method according to claim 6, wherein said oral
immunotolerization prevents the production of anti-Factor IX
antibodies in said patient.
12. A method of treating a patient having hemophilia B
comprising orally administering to said patient a hemophilia
B symptom preventing or ameliorating amount of a milk
derivative concentrate of recombinant human FIX consisting
essentially of a biologically active Factor IX derived from
milk produced by a transgenic pig whose genome comprises
a stably integrated exogenous DNA molecule encoding
human Factor IX, wherein said human Factor IX was purified
and concentrated over the Factor IX present in said milk of
said transgenic pig, and mixed with a pharmaceutically
acceptable carrier to form said milk derivative concentrate,
wherein said amount of orally administered Factor IX com
prises from 2.5 mg/ml to 250 mg/ml of Factor IX, and results
in reduced bleeding time in said patient as compared to no
administration of Factor IX to said patient, achieving a thera
peutic effect in treating hemophilia B and achieving oral
immunotolerization of said Factor IX.

is milk or a milk derivative.

15. The method according to claim 12, wherein said human
Factor IX was purified via chromatography.
16. The method according to claim 12, wherein said human
Factor IX comprises a specific activity of about 150-250
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U/mg in 5 mM Ca".

17. The method according to claim 12, wherein said oral
immunotolerization prevents the production of anti-Factor IX
antibodies in said patient.
18. The milk derivative concentrate according to claim 1,
wherein said human Factor IX was purified and concentrated
by 25 to 50 fold over the Factor IX present in said milk of said
transgenic pig.
19. The method according to claim 6, wherein said human
Factor IX was purified and concentrated by 25 to 50 fold over
the Factor IX present in said milk of said transgenic pig.
20. The method according to claim 12, wherein said human
Factor IX was purified and concentrated by 25 to 50 fold over
the Factor IX present in said milk of said transgenic pig.
k
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